Abstract. In this study, we described the effectiveness of metformin on Japanese type 2 diabetes patients receiving sulfonylureas and the clinical characteristics of the patients whose glycemic control were significantly improved with metformin administration. Our results showed that the reduction of glycohemoglobin (HbA 1C ), serum concentration of total cholesterol, and diastolic blood pressure was statistically significant through the administration of metformin. The clinical characteristics of the patients who responded to metformin therapy exhibited lower systolic blood pressure in addition to higher HbA 1C value just before administration of metformin when compared with ∆HbA 1C (HbA 1C 6 months after administration of metformin -HbA 1C before administration of metformin). Moreover, effectiveness of metformin was weakened, in comparison with non-hypertensive patients, even though the blood pressure of hypertensive patients was reduced to normal range by medication with antihypertensive drugs. But average reduction of HbA 1C level of hypertensive patients without antihypertensive medications was smaller than those of patients with high blood pressure with such medication. These results suggested that high blood pressure and hypertension phenotype itself were suppressive factors of metformin but antihypertensive therapy itself enhanced the effectiveness of metformin regardless of the improvement of blood pressure.
THE earliest determinant of progression to type 2 diabetes is a loss of early insulin secretion, a defect which results in postprandial hyperglycemia and is often believed to reflect insulin resistance. But the recent diabetic population including Japanese shows an increased background of insulin resistance resulting in metabolic syndrome [1] . To improve insulin resistance, metformin, one of the biganides, has been prescribed to diabetes patients for more than four decades. The effectiveness and safety of metformin for diabetes has been re-confirmed by DeFronzo et al. in 1995 [2] , and by the UKPDS 34 announcement in 1998 [3] . However, the typical therapeutic dosage of metformin in Japan is 500-750 mg, which is about one third lower than the 2250 mg dosage in U.S. and Europe. The effectiveness of lower dosage of metformin in Japanese was first reported by Ohmura et al. [4] , and Nagasaka et al. [5] . According to the report by Ohmura et al., a significant improvement for fasting blood glucose value was observed at 500 mg and 750 mg of metformin, in addition to sulfonylureas (N = 14) for 6 months, and as a single administration (N = 11) [4] . According to the report by Nagasaka et al., significant improvement of glycohemoglobin was observed by 750 mg of metformin in addition to sulfonylureas (N = 36) for 6 months [5] . Furthermore, increased body weight and a change in lipid metabolism were not observed in the patients. While there are numerous reports on how metformin reduces triglyceride [2] and/or total cholesterol [2] , and increases HDL-cholesterol [6] , in addition to its principal action of blood glucose reduction in U.S. and Europe, such reports are rare in Japanese population. It may be assumed that these differences are caused by the difference in therapeutic dosage in Japan and U.S. / Europe. Next, in comparative standpoint of racial difference, first, Japanese have a lower BMI than American and European. Second, insulin release by a Japanese has been reported to be half to three-fourths of that of a Caucasian, according the minimal model of the Botnia Study [7] , and so a difference in insulin secretion capacity can also be assumed [8] . Third, it has been reported that Japanese have a high ratio of the thrifty "alle" genes, which may be some of the causative genes for Type 2 diabetes, such as the β 3 -adrenaline receptor gene [9] , PPARγ gene [10] , and the adiponectin gene [11] , and so a genetic difference can also be assumed. These factors may influence the difference in medicinal effect in Japan and U.S. / Europe. In this study, in consideration of these backgrounds, we analyzed which clinical factors accelerated or hindered the effectiveness of metformin in Japanese type 2 diabetes receiving sulfonylureas.
Subjects and Methods
For 3 years, from November 1996 to October 1999, we retrospectively investigated 86 outpatients with type 2 diabetes visiting Juntendo University Hospital, who were receiving sulfonylureas, and whose HbA 1C level were in stable condition for more than 3 months, and displayed no change after 6 months of the initial administration of 750 mg metformin and concomitant drugs. Clinical background of the patients including systolic blood pressure (SBP), diastolic blood pressure (DBP), total cholesterol concentration in serum (TCho), HDL-cholesterol concentration in serum (HDLC), triglyceride concentration (TG), body weight (BW), and BMI before and 6 months after admission were compared and indicated in Table 1 .
Statistical analysis
T verification was used to confirm body weight difference and clinical laboratory test values before and after administration of metformin ( Table 3 ). The patients were judged as using BMI, SBP, DBP, and clinical laboratory test value before administration of metformin, according to the modified metabolic syndrome diagnostic criteria [12] as shown below, and then multiple linear regression analysis between those diseases by the stepwise method was performed. F = 2 was determined to be the input standard (Table 4) .
Hypertension was defined as SBP õ130 mmHg and/or DBPõ85 mmHg. Hyperlipidemia was defined as T-Choõ220 mg/dl and/or HDLC<40 mg/dl and/or TGõ200 mg/dl. TG was converted from 150 to 200 mg/dl due to postplandial state. Obesity was defined as BMIõ25 (Table 4) .
Also, patients undergoing medical treatment for various diseases were included into a disease "yes" category and analyzed together (Table 5 ). HYPER-TENSION was defined as SBPõ130 mmHg and/or DBPõ85 mmHg and/or medication for hypertension. HYPERLIPIDEMIA was defined as T-Choõ220 mg/dl and/or HDLC<40 mg/dl and/or TGõ200 mg/dl and/or medication for hyperlipidemia. Obesity was defined as BMIõ25. Furthermore, in order to determine whether the effect of metformin is influenced by antihypertensive drugs, the patients were categorized into Normal Blood Pressure Group (no drug therapy, no hypertension), Improving Group (with drug therapy, improved blood pressure), Non-Improvement Group (with drug therapy, not improved blood pressure), and Uncontrolled High Blood Pressure Group (no drug therapy, with hypertension). High Blood Pressure Group included Improving Group + Non-Improvement Group + Uncontrolled High Blood Pressure Group. Then the average value ± standard deviation was determined as shown in Fig. 1 , and t verification was performed by arranging the categories as Normal Blood Pressure Group vs High Blood Pressure Group, Improving Group vs Non-Improvement Group, Normal Blood Pressure Group vs Improving Group.
Results
There were 86 cases of 750 mg metformin administration. The average value ± standard deviation in Age, Gender, BMI, BW, and clinical laboratory test Table 2) .
To generalize the clinical factors influencing ∆HbA 1C , multiple linear regression analysis was performed. SBP was positively (p = 0.025) and HbA 1C was negatively (p = 0.001) correlated. TG (p = 0.404) was excluded here (Table 3) .
The multiple classification analysis of the clinical factors for effectiveness of metformin on ∆HbA 1C selected SBP, suggesting the possibility of involvement of hypertension in the improvement of blood glucose by metformin. Next, metabolic syndrome diagnosis criteria was used to classify groups of hypertension, hyperlipidemia, and obesity, which are factors in arterial sclerosis, according to the clinical laboratory test value before metformin administration. Multiple linear regression analysis was performed on ∆HbA 1C and each disease. Here, hypertension showed a positive correlation (R 2 = 0.162 p = 0.002) to ∆HbA 1C (Table 4) . Meanwhile, there was no difference in HbA 1C before administration of metformin, in the presence or absence of hypertension.
Criteria of metabolic syndrome diagnosis were added to each disease group for patients receiving drugs for each disease. Thus, patients who had been treated for hypertension or hyperlipidemia were included in each disease group, and multiple linear regression analysis was performed again. As expected, hypertension (indicated as "HYPERTENSION") showed a positive correlation (R 2 = 0.166 p = 0.001). (Table 5 ) These results suggested the possibility that the hypertension phenotype itself may be a suppression factor of the effectiveness of metformin even if the blood pressure was successfully reduced with antihypertensive drugs. Meanwhile, there was no difference in HbA 1C before Fig. 1 administration of metformin, in the presence or absence of hypertension. In order to confirm the possibility, t verification was performed to see if the effect of metformin was influenced by drug therapy for hypertension or not. Mean blood pressure of each group (see footnote of Fig. 1 ) is shown in Fig. 1a . Mean systolic blood pressure of Normal Blood Pressure Group (NBP) was significantly lower than those of High Blood Pressure Group (HBP) (including Improving Group, NonImprovement Group, and Uncontrolled High Blood Pressure Group), Non-Improvement Group (NIM), and Uncontrolled High Blood Pressure Group (UHBP). Mean systolic blood pressure of Improving Group (IM) was significantly lower than those of NIM and UHBP, but did not show significant difference in comparison with that of NBP. Diastolic pressure of NIM was significantly higher than those of NBP and IM. As shown in Fig. 1b , stronger glucose-lowering effect of metformin was observed in NBP with a significant difference (p = 0.001) in comparison with HBP. Between the glycemic control of IM and that of NIM, there was no significant difference (p = 0.694), suggesting that the influence of hypertension on the effectiveness of metformin did not depend on the effectiveness of antihypertensive drugs on the blood pressure in hypertensive patients. When we compared the effectiveness of the metformin in patients whose blood pressure was high, metformin showed more significant effects in NIM on lowering the blood glucose and ∆HbA 1C than those in UHBP (p = 0.018), suggesting that drug therapy itself made metformin more effective, although blood pressure was not sufficiently reduced. When we compared the effectiveness of the metformin in patients whose blood pressure were within normal limits, metformin showed greater effects in NBP on lowering the blood glucose and ∆HbA 1C than those in IM (p = 0.198) but the difference was not significant. Antihypertensive drugs for the patients belong to IM and NIM were compared. The number of categories of the antihypertensive drugs in NIM group (1.60) was slightly larger than that of IM group (1.38) but the difference was not significant. Inhibitors of angiotensin converting enzyme which have been widely reported to improve insulin resistance in type 2 diabetes patients, were slightly more often prescribed in NIM group (9/15) than IM group (3/8), but the difference was not significant. Angiotensin receptor antagonist was prescribed for only one patient in NIM group but no one in IM group.
Discussion
A lot of reports on the usefulness of metformin on type 2 diabetes patients receiving sulfonylureas with both the dosage of 1750-2250 mg used in Europe and America and that of 500-750 mg used in Japan have been published [2, [4] [5] [6] . In this study the patients receiving a dosage of 750 mg of metformin while receiving sulfonylureas were targeted. Significant reduction of HbA 1C (-0.79 ± 1.18%) was observed after 6 months administration of metformin. While an improvement of lipid metabolism in European and American populations has been reported [2, 6, 13, 14] , no such improvement has been reported in a Japanese one [4, 5] . This may be attributable to the difference in the setting of the therapeutic dosage, BMI, insulin secretion capacity, and 'thrifty' genetic factors between Japanese and American / European populations. However, a significant reduction of total cholesterol of 9.17 ± 27.40 mg/dL (p<0.003) could be observed in this study.
It has been reported that the effect of metformin is through AMPK in a rat hepatic cell primary culture [15] . In this report, metformin phosphorylated and inactivated acetyl-CoA carboxylase via activation of AMPK and suppressed the synthesis of fatty acids and promoted fatty acid β-oxidation. Moreover metformin has been reported to down-regulate the expression of sterol regulatory element-binding protein 1, resulting decrease of enzyme activities related to the fatty acid synthesis, such as fatty acid synthase, L-PK, and S14 [15] . They concluded that these regulations with metformin reduced the lipid contents within the liver and improved insulin resistance. Also Garber et al. has reported that improvement of HbA 1C depended on the dose of metformin [16] . Furthermore, DeFronzo and Gooodman [2] and Perriello et al. [17] have reported that the effect of metformin was not dependent on BMI. Through these reports, it can be assumed that, not only glucose but also lipid metabolism can be improved by increasing the therapeutic dosage of metformin, even in Japanese population.
In this study, a reduction of 4.50 ± 10.50 of DBP by the administration of metformin was observed. Reports on the improvement of blood pressure have been published by Landin et al. [13] and Fanghanel et al. [14] and a significant reduction in SBP and DBP was also observed. Meanwhile, no weight change was observed during these studies.
Improvement of glycemic control without increase of body weight by metformin treatment have been reported [2] [3] [4] [5] and the mechanisms of which also have been reported on suppression of appetite [18] , increase in energy consumption [18] , and suppression of glucose absorption from the intestinal tract [19] . It has been reported that metformin suppressed the appetite as a gastrointestinal side effects through the 5-HT 3 receptor-independent release of 5-hydroxytryptamine (5-HT) via neuronal and non-neuronal mechanisms [20] .
In this study, the clinical characteristics that influences the effectiveness of metformin for Type 2 diabetes was analyzed. To our knowledge, reports on those of the responder have been extremely rare, and only reports stating the influences by body weight on effectiveness of metformin in IGT population [21] and the lack of them [17, 22] could be found.
While high value of HbA 1C before start of metformin treatment accelerated the effect of metformin as a metric variable, SBP was also chosen as the predictor lowering effect of metformin, and also hypertension phenotype was chosen as the predictor inhibiting it in the phenotype disease groups, irrespective of the addition of patients who showed normal blood pressure undergoing drug therapy or not, with a multiple classification analysis. These results strongly suggested that "hypertension" suppressed the hypoglycemic effect of metformin. Once hypertension is present, it may suppress the effect of metformin even if the blood pressure was improved to normal range by antihypertensive drug therapy. However, medication of hypertension weakened the suppressive effect by hypertension regardless of the improvement level or kind of antihypertensive drugs. So these results suggested that drug therapy for hypertension is beneficial on glycemic control of the type 2 diabetes patients who have hypertension and are being treated with metformin.
Numerous studies have reported that a defect of insulin action in skeletal muscle was observed in spontaneously hypertensive rats [23] [24] [25] . On the other hand, it has been previouly reported that an antidiabetic action of metformin was observed predominantly in liver but that it was less effective in skeletal muscle [26] . So the reason why the hypoglycemic effect of metformin decreases in patients with hypertension may be due to the inability of this drug sufficiently improve insulin sensitivity in skeletal muscle, a phenomenon which is often observed in hypertensive patients. While antihypertensive drugs including inhibitors of angiotensin converting enzyme [24, 25, 27] and calcium antagonists [28, 29] partially improve the insulin sensitivity in skeletal muscle, metformin may efficiently ameliorate glycemic control via improvement of insulin sensitivity in liver. The reason why there was no difference in hypoglycemic effects of metformin between IM and NIM groups, although mean systolic pressure of NIM group was significantly higher than that of the IM group, may be due to the prescription of larger numbers of antihypertensive drugs and higher ratios of inhibitors of angiotensin converting enzyme. Further studies are needed to examine the relationship between hypertension and effect of metformin.
In conclusion, it has been reported that metformin had sufficient effect in Japanese type 2 diabetes patients receiving sulfonylureas. The results of the present study suggested the possibility that hypertension may be a suppressive factor to the effectiveness of metformin. Medication with antihypertensive drug on these patients should be regarded as important because it partially recovers the effectiveness of metformin which is suppressed by the hypertension phenotype.
